Valuation
- Market cap
- 15,196,000
- Revenue TTM
- $0
- Net income TTM
- $-121,340,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.55
Trading
- Volume
- 68,104,898
- Avg volume
- 1,921,126
- Day's range
- $0.21 – $0.35
- Shares out
- 72,327,000
- Stochastic %K
- 0%
- Beta
- 0.33
- Analysts
- Hold
- Price target
- $7.75
Company profile
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc....
Show more
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 344 4190
- Website
- https://acumenpharm.com
- Address
- 1210-1220 Washington St., Suite 210, Newton, United States
Latest news
No headlines yet.
